Sys Rev Pharm 2020; 11(5): 259 – 273
A multifaceted review journal in the field of pharmacy
E-ISSN 0976-2779 P-ISSN 0975-8453

Solid Lipid Nanoparticles (SLN) as a Novel Drug Delivery System: A Theoretical Review

[1*]Ahmed A.A Alsaad, [2]Ahmed A. Hussien, [3]Mowafaq M. Gareeb
[1]University of Basrah, college of pharmacy, Iraq
[2]University of Baghdad, college of, pharmacy, Iraq
[3]University of Baghdad, college of pharmacy, Iraq
***Address for correspondence:** Ahmed.alsaad2ph@gmail.com

Article History: *Submitted: 06.03.2020* *Revised: 10.04.2020* *Accepted: 11.05.2020*

ABSTRACT

The introduction of solid Lipid Nanoparticles (SLN) for the first time in late 1991 to be a substitute transporter system to what known old colloidal carriers, like emulsions, liposomes, and polymeric micro- and nanoparticles. SLN has merits and potentialities of Classical structures except avoiding some of their common and known disadvantages. This paper reviews SLN production techniques, The integration of drugs, the capacity to load and the release of drugs, with particular emphasis on drug discharge techniques. Issues relating to the introduction of the SLN into the pharmaceutical industry, like the excipients position.

From the very beginning a special and wide interest paid to Lipid nanoparticles (LNPs) during the last decade. Nanostructured lipid transporters strong lipid nanoparticles (SLNs) become the most two essential forms of nanoparticles formed from lipids. SLNs were designed to be able to overcome certain restrictions types of colloidal vectors, like liposomes, emulsions, and polymeric nanoparticles as they possess bright sides like strong discharge profile and guided distribution of drugs with the most perfect physical health. NLCs will amend the SLNs in the next generation of lipid nanoparticles in a way that enhances stability, safety and capacity loading.

This paper focuses on methods to reduce toxic effects using advanced production techniques such as homogenization and solvent evaporation. As it facilitates way for the solid lipid nanoparticles approval as novel or targeted medication distribution system by using several recent analytical techniques like electron microscopy and dynamic light scattering (DLS), differential scanning calorimetry (DSC), nuclear magnetic resonance, atomic force microscopy and their evaluation parameters concurrent with the application.

Conclusion

- Solid lipid nanoparticles (SLNs) represent a transport system alternative to conventional colloidal carriers.
- SLNs combine the advantages of traditional and modern systems if some of their major difficult proceedings are eliminated.
- SLN production techniques include drug incorporation, drug loading and release capacity, with a special focus on drug release methods.
- SLNs as novel system and targeted drugs delivery method through using recent techniques.

Keywords: Solid lipid nanoparticles, physical stability, preparation methods, applications

Correspondence:
Ahmed A. A. Aslaad
University of Basrah, College of Pharmacy, Iraq
E-mail: Ahmed.aslaad2ph@gmail.com

DOI: 10.31838/srp.2020.5.39

INTRODUCTION

Nanoparticles of solid lipids (SLN) introduced for the first time in December 1991 to be a system of medication carrier to what called traditional colloidal carriers, that system that includes of nanometer ranges of spherical stable lipid cells, which are often scattered in fluid surfactant arrangement or in water [1].

The targeted delivery system is one of the toughest study areas in pharmacy. A new challenge has appeared for improving drug delivery via advancing the system of colloidal delivery like liposomes, micelles, and nanoparticles.

SLN encompasses the polymeric nanoparticle's superiority, lipid emulsion, and liposomes but at the same time, The SLN have many advantages such as good biocompatibility, non-harmful, stable against mixture, sedate spillage, hydrolysis, biodegradable, physical table, and good carrier for lipophilic drugs. But anyway several differences and contradictions between lipid emulsion and liposomes are found [2].

SLNs and NLCs have an amazingly large number of properties which make them beneficial for various tasks like topical Drug delivery: parenteral, dermal, pulmonary and topical. Those Products were designed to minimize the reactions of exceptionally powerful medications added, and to build the treatment efficiency remarkably. Also worthy of mention they introduced a strong program in the field of transferring gene and in industrializing cosmetic, and food materials. However, due to the above said limits and barriers associated to them, the entire quantity of production in the markets is still inadequate, and in a narrow range [3].

Nanotechnology is a method to solving the problems posed by traditional drug delivery systems. Solid Lipid nanoparticles show great features concerning therapeutic purposes. As most of the active pharmaceutical ingredients (APIs) are poorly water-soluble and under development; absolutely have low bioavailability. Their being prepared with physiologically well-tolerated lipids is the main advantage and what makes them convergence point and a corner stone in this process. Solid lipid nanoparticles (SLNs) as new lipid-based nanocarriers running in size from 10 to 1000 nm. SLNs were created at the very beginning to be able to confront polymeric nanoparticles difficulties. By putting forward physiological safe lipids instead of polymers to prepare lipid nanoparticles [4].

Many difficulties were found by Formulation scientists the clearest of them were low solubility improving and bioavailability of the recently invented drugs. One of the breakthroughs to confront the above-mentioned problems is to formulate the new particulate carrier system. The presence of multiple colloidal drug-bearing structures may the scientists' queries about what of those can be the most relevant carrier system for the required target (Figure 1).

As the taking into account the following aspects: [5] Drug loading ability, adequate drug positioning, in vivo transporter structure fate (contact with the adjacent bodily fluid, proportion of deterioration, aggregation in organs, etc.), poisonousness, severe in addition to chronic, Large-scale development and overall formulation costs..[6-8].



Figure 1: SLN chemical structure [9]

Nano sized drug delivery systems were evolved to able to confront the following arising problems:

A) Low or highly variable drugs concentrations after peroral administration because of its main disadvantages such as, low absorption, quick metabolism, and elimination.

B) Poor drug solubility that includes iv injections of aqueous drug solutions.

C) Drug delivery associated with high toxicity of other tissues. (Ex: Medicines for Cancer) [10].

Worthy Mentioned, that several processing methods are required for LNPs, like elevated pressure homogenization (HPH), dissolvent emulsification / evaporating, supercritical extracting of emulsion fluid, ultrasonic or fast-moving homogenization in addition to spray drying [11-14].

Two processes have emerged from the HPH, hot and cold structures. Two key processing techniques exist that dissolve or solubilize the drug in the lipid fused at 5-10 ° C above fusion level. [15].

LNP's other names is Liposomes are traditional lipid-based formulating models discovered in 1965 and widely studied in the last few years. A liposome is known as a spherical vesicle surrounded by a lipid bilayer membrane, with an aqueous internal cavity. The name Liposome originates from the following two Greek terms,

- 'Lipid' is fat, and also its definition.
- 'Soma' that means body.

In recent decades they have been studied for dermal, medicinal, and cosmetic studies. As a pharmaceutical carrier, liposomes have specific qualities such as defense against enzyme dilapidation, low poisonousness, versatility, biocompatibility, fully biodegradable and non-immunogenicity [16-18], nevertheless, many defects, like short shelf life, poor durability, low efficiency of encapsulation, quick reticuloendothelial elimination, cell interactions or adsorption, and inter membrane transferring hinder its presence in many applications

Despite the fact that liposomes contain lipid nanoparticles that have the advantage of delivering therapies, approaches are needed to monitor the release of drugs and their distribution that may not be loaded into the liposomes. The unavailability of "inexpensive" pharmaceutical liposomes and technological problems is one of the obvious reasons why the drug was not released and delivered [19].

Classification of nanoparticles



Figure 2: Classification of nanoparticles [20]

The toxic effects of metals and polymers that are used in nanoparticles preparation are considered the essential concern with the metallic and polymeric nanoparticles, as the lipids that are used in the preparation are usually categorized as GRAS (Generally known as secure) materials [21]. Lipid nanoparticles have too main categories which are Nanostructured Lipid Carriers (NLC) and Solid Lipid Nanoparticles (SLN) (Figure 2).



Figure 3: The main difference between both basic kinds of lipid nanoparticles [20].

Lipid nanoparticles are brought from solid at the temperature lipids room, fat emulsions, and liposomes are two main advantages of the polymeric nanoparticles advantages SLNs have along with the ability to successfully solve issues associated with physical and chemical security of medication (Figure 3), medication distribution and consumption. [22]

Appropriate way of minor molecular weight medications delivery and macromolecules like proteins, peptides or genes to cells and tissues and it is working on protecting them from enzymatic degradation are offered by Drug delivery Nanotechnology. [23].

The use of lipids as a certain carrier for polymeric nanoparticles, mainly for lipophilic medication and lipid nanoparticles are called as solid lipid nanoparticles (SLNs) [24].

Particles in the ranges of nanometers, are often scattered in water or aqueous surfactant oil. SLN originates from solid hydrophobic heart with a single layer of phospholipids. Phospholipid hydrophobic chains are built in a fat matrix and possess the ability to convey hydrophilic or lipophilic or diagnostic medicines [25].

THE MAIN ADVANTAGES AND DISADVANTAGES OF SLN.

SLN's Advantages

It reduces the risk of chronic and acute poisonousness and prevention of organic solvents in creation method through Biodegradable physiological lipids usage.

- It improves poor water soluble molecules bioavailability.
- It enhances medication entrance into the skin through applying dermal by what called Site specific distribution of medications
- It controls drug release Possibility and also drug targeting.
- It protects chemically labile reducing agents in the intestine and also it safeguards delicate molecules from external world.
- SLNs are more stable compared to liposomes.
- It fosters the trapped bioactive bioavailability and integrated labile chemical production compound.
- Highly focuses on functional compound accomplished.
- Lyophilization is possible [26-28].

Shorten its faults in the following

SLN's Disadvantages

- Low medicine packing capacity.
- Medication exclusion following polymeric change during storing.
- Comparatively high dispersed water volume (70-99.9%).
- The bounded capacity of loading of water-soluble drugs during the manufacturing cycle due to partitioning effects [29].
- Gelation tendency.
- Incredible motion of polymeric transition. [30-32].

The rationales for rising attention in the lipid system

1. Lipids increase the oral bioavailability and decrease the heterogeneity of plasma profiles.
2. Effective characterization of lipoid excipients.
3. A growing ability to deal and solve technology transition challenges and scale-up development problems [33].
4. SLN's Formulation

General components comprise solid lipid(s), emulsifier(s) and water. The word lipid possesses a wider meaning and contains triglycerides (e.g. tristearin), imperfect glycerides (e.g. Imwitor), fat acids (e.g. stearic acid), and steroids (e.g. cholesterol) and waxes (e.g. cetyl palmitate). The whole emulsifiers kinds (concerning charge and molecular weight) aim preserve the lipid scattering General components comprise solid lipid(s), emulgator(s), and wind. The word lipid has a wider definition and contains triglycerides (e.g. tristearin), incomplete glycerides (e.g. Imwitor), fat acids (e.g. stearic acid), and rogens (e.g. cholesterol) and waxes (e.g. cetyl palmitate). The purpose of these types of emulsifiers (related to charge and the weight of molecular) is to preserve the lipid scattering. Noted worthy that, the emulsifiers combination might prevent particle agglomeration that seems more efficient [34-37].

Preparation methods of solid lipid particles

To a large extent the achievement of SLNs relies on the preparing process which in effect impacts the size of the atom, the capacity of the medication to charge, the release of medication, medication steadiness etc. There are various methods for producing finely detached lipid nanoparticle dispersions [16]. The methods of preparation include:

SLN preparation with homogenization at high pressure

SLN are nanoparticles consisting of solid lipids with a mean diameter of about 50 to 1000 nm by photon correlation spectroscopy (PCS). Normal constituents comprise solid lipids, surfactants, and water. The word lipid has a general meaning and comprises triglycerides (for example, tristearin), incomplete glycerides, fat acids (for example, stearic acid), hormones (such as, cholesterol) and waxes (like, cetyl palmitate). The surfactant forms (respect for charge and molecular weight) are aimed at settling lipid diffusion .

At the end of the last century, the SLN was advanced and regarded as beneficial medication conveyer systems, particularly with the purpose of giving a constant release profile to the incorporated vigorous materials. As a matter of a fact, in comparison to fluid lipid formations, like nano emulsions, medication movability has low level in solid lipids than in fluid oils. Unlike polymeric nanoparticles, they exhibit better biocompatibility as they are composed of lipids just like physiological ones, hence the poisonousness is decreased. Furthermore, SLN is physicochemical unchanging and might be created effortlessly on a large manufacturing scale, and the basic elements and making expenses are quite little [38-40].

SLM has the equal structures to SLN, however greater atom bulk (>1000 nm), indicating that their application areas and administering ways may be diverse.

various methods for making nano- and micro particles with solid lipids exist: usually, Formulating nano-and micro particles as precursors necessitates a distinct structure or pattern, apart from that, particles are made by using a certain tool.

Emulsions (hot homogenization method, dissolve scattering process, PIT strategy, dissolvable dissipation dispersion from emulsions), micro emulsions (diluting micro emulsion and micro emulsion cooling procedures), solutions of micelle (cooling method) are the most important precursors. Certain preparing ways are grounded on supercritical liquids. The most significant methods including utilizing a specific device consist of: membrane contactor method, spray-drying, spray-congealing and electro spraying [41].

The scientific of hot homogenization and the methodology of cold homogenization are the most common two production techniques for SLN [42-44], the medication is melted or solubilized For both of them in the lipid and dissolved at around 5± 108C above fusion level. About the technique of hot homogenization, the medication containing melt is spread under mixing at a specific temperature within a fluid watery surfactant solution. Consequently, the pre-emulsion obtained is normalized utilizing a cylinder hole homogenizer (for example Micron LAB40), the hot O/W nanoemulsion formed is chilled off to the atmosphere of room, at the same time the lipid is recrystallized and it prompts strong lipid nanoparticles. Definitely, this care requires to be taken in lipid happens recrystallization. For glycerides comprising of short-chain unsaturated fats (for example Dynasan 112) and low dissolving point glycerides (excessively near room temperature), it seems appropriate to chill the nanoemulsions off to try and lower temperatures to begin recrystallization. It also has the ability to begin recrystallization, like, by lyophilization. The hot homogenization method is also useful for medications with a certain temperature affectability due to the relatively short vulnerability to higher temperatures. The cold homogenization technique can be extended in the case of extremely temperature-sensitive compounds. This method would also be used while defining hydrophilic medications, since they might differentiate between the combined lipid and the water stage during the cycle of hot homogenization. The medication containing lipid dissolve, the strong lipid ground to lipid micro particles (around 50±100 mm) is reduced for the cold homogenization method, what is more, micro particles of lipid are distributed in a cool surfactant arrangement that yields pre-suspension. This pre-suspension is then homogenized at or beneath temperature of a room, the cavitation powers are sufficiently high to split the lipid micro particles. This procedure keeps away from, or limits, the liquefying of the lipid and along these lines diminishing hydrophilic medications loss to the water stage. Absolutely, the distinction between the lipid dissolving point and the temperature of homogenization must be adequately huge to avert the liquefying lipid in the homogenizer. The homogenization procedure attempts to raise the temperature of the item (for example 10±208C per homogenization cycle) and there are a few pinnacles of temperature in the homogenizer. To plainly diminish the hydrophilic compound's misfortune, water can be subbed with fluids of low dissolvability for the item, for example oils or PEG 600, during the aqueous process of SLN dispersion. SLN production in oil or PEG 600 is ideal for medication conveyance via mouth, since this scattering might be occupied straightforwardly into delicate gelatin containers. (Figure 4).



Figure 4: Hot and Cold High Pressure Homogenization Technique in the Production of SLN/NLC [9].

SLN Formulated with Micro Emulsion Technology

Micro emulsions are straightforward or somewhat pale blue arrangements comprising of a lipophilic stage (for example lipid), a co-surfactant and a surfactant and water in numerous cases. The word "micro emulsion" is debated with controversy. Micro emulsions are not currently considered a genuine emulsion with high beads, yet are regard as a basic arrangement [45]. The micro emulsions demonstrate the characteristics of genuine macro emulsions (for example little molecule volumes are probably dictated by light dissipating of laser) and the characteristics of a genuine arrangement simultaneously (for example drugs have a micro emulsion immersion dissolvability and do not imply a circulation coefficient as in macro emulsions). Adding water to a micro emulsion results in accumulation of small particles formed in the lipid process. This influence is taken advantage of in Gasco's SLN preparation process [46]. To frame a micro emulsion with a lipid being strong at the atmosphere of room, the micro emulsion must be formed at a temperature over the softening purpose of the lipid. The lipid (unsaturated fats and additionally glycerides) is liquefied, a blend of water, co-surfactant(s) and the surfactant is warmed to a similar temperature as the lipid and applied to the lipid liquefy under gentle mixing. At the point when the mixes are blended in the accurate proportion for the formation of micro emulsions A straightforward, thermodynamically stable framework is shaped. This micro emulsion is then distributed under a moderate mechanical mixture in a cold aqueous medium (2±38C), thereby guaranteeing that the little volume of the particles is because of precipitation and not precisely brought about by a blending strategy [47-50]. Co-surfactants and Surfactants incorporate lecithin, biliary salts, yet in addition alcohols like butanol [51]. Excipients, for example, butanol are less favored as for administrative angles. From the specialized perspective of the particles of lipid in water is a weakening of the framework, which prompts a shortage in the SLN dispersion

Co-surfactants and surfactants incorporate lecithin, biliary salts, alcohols, for example, butanol [51], as well. As for regulatory aspects, excipients such as butanol are less preferred. From the scientific perspective of the lipid particles in water, the method is condensed, which results in a lack of SLN dispersion solid content. It is highly desirable for certain technical operations to possess a high lipid strong substance, for example 30%. A model is the exchange of the SLN scattering via the granulation process to a dry product like (tablet, pellet). The dispersion with SLN might be utilized as granulation fluid, nevertheless when particle content is low or poor what arises a must of water removals. Enormous scope creation of SLN using the micro emulsion strategy likewise seems to be practical at Vectorpharma (Trieste, Italy) and by and by a work in progress. The micro emulsion is set up in a huge temperature-controlled tank and in this way siphoned from that tank into a cold water tank for the stage of precipitation [52]. Significant procedure parameters throughout scaling are, for example, micro emulsion and water temperatures, yet in addition temperature streams in the medium of water and blending hydrodynamics that ought to adjust as meager as conceivable through scaling in order to retain a similar item characteristics.

Lipid nanopellets and lipospheres

Speiser developed the lipid nanopellets for oral conveyance and it produced them Stirring or sonication by scattering a liquid lipid in a surfactant solution. The molecule size obtained is measured by the thickness of the stirrer force. Anyway, a blend of nanoparticles and micro particles is acquired [53-55].

The surfactant is likewise fused into the lipid process during the development of lipid particles, as one moves towards lipid solubilization, the more surfactant it is available, the more it is consolidated prompting decreased lipid molecule crystallinity (unpublished data). Higher concentrations of surfactants may be suitable for oral organization, the path to which nanopellets were proposed by the patent [56], Be that as it may, may mess some up for different courses, for example, intravenous administration. Domb-developed lipospheres are 'strong, water- unsolvable micro particles which possess a phospholipid covering implanted on their outside surface [47±49]. The patent cases that lipospheres consist of a center made out of a strong hydrophobic substance at the temperature of room and a phospholipid covering around the center. The normal distance across of the particles is 0.3 to 250 mm. furthermore, they are set up by softening the center content, including phospholipid alongside a fluid medium and scattering the dissolved substance at high temperatures using multiple simultaneous methods, much like electric stirrings or Sonics. Cooling gives rise to solid liposphere. The liposphere is limited to one balancing out operator which alludes the layer of phospholipids. For SLN, suspensions were documented to stabilize only with phospholipid, which sometimes tends to frame semi-strong salve like gels [57]. The formation of gel is avoided by the presentation of a co-emulsifier not ensured by the patent of liposphere. As a rule the SLN gave by our gathering is balanced out by double or ternary surfactant blends, which guarantee ideal long haul physical security.

Particles hastened with lipids

The lipid precipitates form nanoparticles just After solvent evaporation [58]. To use organic solvents a clear disadvantage must appear. In addition to that, Other challenges appear like when the creation of polymeric nanoparticles by dissolvable dissipation is scaled up. Conversely, SLN provided by strong pressure homogenization has the benefit of evading the utilization of dissolvent. Even solid lipid particles can lead to precipitation technique that can be compared to the polymeric nanoparticles production by solvent evaporation. This procedure is distinguished by its solvent requirement, in contrast to, the glyceride SLN is broken down in a natural dissolvable (e.g., chloroform) and emulsified in a fluid procedure.

Membrane contactor technique

In this process (Figure 5), two layers, one aqueous and the other organic, are separated in a water bath where high pressure is used in this way through the membranes of the membrane and a high temperature is used that exceeds the melting temperature of the fat molecules that form during this stage small fat drops and crystallize in their final form when the temperature is reduced To 20 ° C. The aqueous and organic layers can be isolated to be used in the liquid phase where nitrogen and high pressure are used to maintain the aqueous and organic layers of the next stage.



Figure 5: Steps of forming lipid particles in a membrane contactor.

This process consists of three steps:

1. Dissolve the matrix consisting of a mixture of fats, surface materials, polymers, and medicine at a temperature of 55-70 ° C.
2. Add hot water with continuous vibratory stirring to form a small emulsion.
3. Cooling to 20 ° C with continuous stirring until the SLNs are formed [59-61].

Incorporation of medications and ability to load

The basic components of SLNs are that they contain one fat and one emulsion or a group of emulsions depending on the type of fat and emulsion, and the method of preparing particle size. It has been found that the surfactant used to prepare SLNs varies according to the type of particle to be prepared.

Factors influencing the load potential of the drug in fat:

1. Drugs Solubility in liquid lipid.
2. Lipid fusion miscibility and the drug melting.

3. Physical and chemical and arrangement of matrix of solid lipids.
4. Polymorphic state of lipid matter [62, 63].

There are several different drugs integrated into the SLN, models are given in Table 1. An exceptionally basic factor to decide a medication bearer framework's appropriateness is its ability to expense. The capability of stacking is usually communicated in percentage identified with the lipid step drug matrix lipid. (Drug integration with loading capacity of usually 1±5 percent, up to 50 percent for Ubidecarenone loading capacity, was tested. Recorded capacities of 10±20% for tetracaine and etomidate, up to 5% for retinol, 20% for coenzyme Q10 and 20±25% for cyclosporine.
The first form (solid solution) is several types: the solubility in liquid lipid in this class of drugs is bigger than in solid lipid, hence preserved by solid lipid from decomposition. This type of NLCs is resembling emulsions .

The second class (drug enriched shell) is the shapeless kind (non-crystalline matrix), a category which does not have crystalline construction and hence stops the exclusion of stacked medication which is known as formless kind in which crystals are shaped in the course of cool and to keep from it, should be utilized some lipids blend.
The third type (lipid shell) is the incomplete method of mixing of solid and liquid fats (oil) into different lipid constructions. Relevant circumstances in the crystallization process result in an extremely disordered one. Defective lipid matrix frame that shows a distance between fat acid triglyceride chains in crystal and hence boosts the capacity of the medications to join the matrix.
Figure 6 and table 2 shown three sorts of drug integration models (model of solid solution (left), medication enhanced shell core models (central), and medication enhanced core models (right) [19].



Figure 6: Three drug incorporation models.

Table 1: Drugs incorporated examples in SLN, all SLN were prepared by high-pressure homogenization apart from the SLN by Gasco (microemulsion technique)[64]

Corresponding Author/ Research Group	Referenec	
Timolol		[102,104]
Deoxycorticosterone		[103]
Doxorubicin		[106]
Idarubicin		[106]
[D-TRP-6]LHRH		[107]
Pilocarpine	Gasco	[108]
Thymopentin		[109]
Diazepam		[15]
Gadolinium(III)complexes		[44]
Progesterone		[66]
Hydrocortisone		[66]
Paclitaxel		[125]
Retinol		[55,56]
Coenzyme Q10	Gohla	[58]
Vitamin e Palmitate		[85]
Aciclovir	Lukowski	[24,26]
prednisolone		[37,61]
Tetracaine	Mehnert	[61,68]
Etomidate		[53,61,68]
Cyclosporin		[60]
Sunscreens	Muller	[84]
Nimesulide	Patravale	[126]
Azido-3'deoxythymidine palmitate	Phillips	[19,20]
Azido thymidinr palmitate		[21]
Oxazepam		
Diazepam		
Cortisone		
Betamethasone valerate	Westesen	[52]
Prednisolone		
Retinol		
Menadione		
Ubidecarenone		
Camptothecin	Yang	[22,23]
Piribedil	Yazan	[28]

Table 2. Three models of drug incorporation into SLNs[20]

Solid solution model	Core-shell model (drug-enriched shell)	Core-shell model (drug-enriched core)
Formation of this model in cold homogenization technique	Formation of this model in hot homogenization technique	Dispersion cooling leads to a supersaturation of the drug which is dissolved in the lipid.
Using no drug-solubilizing surfactant	Formation of lipid core at recrystallization temperature of lipid	Precipitation of drug in melted lipid
Drug dispersed in lipid matrix	Formation of lipid core at recystllization temperature of lipid	Precipitation of drug in melted lipid
Drug dispersed in lipid matrix	Cooling of the obtained dispersion leads to re-partitioning of the drug to the lipid phase	Finally, further cooling lead to recrystallization of the lipid
There is a strong interaction between lipid and drug	Concentration of drug in surrounding membrane	Formation of drug-enriched core

SLN'S CHARACTERIZATION

The SLNs have been classified for physical traits like color, perfume and steadiness while the gel preparations have been estimated for color, odor and pH [65].

Incorporated Medication assessment

Measure of medication joined in SLNs impacts the discharge attributes; hence it is very important to measure the amount of incorporated drug. The entirety of medication typified for each unit weight of nanoparticles is by ultracentrifugation, gel permeation chromatography or

centrifugal filtration after partition of the free medication and strong lipids from the watery medium. The drug can be assayed by standard analytical technique such as spectroscopy and HPLC methods.

7.2. Particle size, polydispersity index and possible calculation of the zeta

By the technique of dynamic light dissipating molecule size and polydispersity list of the Malvern Zetasizer Nano ZS (Malvern Instruments, UK) used to assess SLNs). Dispersions have been weakened with twofold refined water to guarantee the light dispersing intensity is inside the affectability go of the instruments. All of these samples were triplicated and the final outcomes were considered as mean ± standard deviation (Figure 7).



Figure 7: Influence of zeta potential on the repulsion/coalescence of particles [9]

% Entrapment Efficiency [66]

Calculating the concentration of un trapped medication in the lipid dispersion The competence of trapping (percent EE) was calculated [58]. In short, Centrifugation of the SLNs during 30 min, 4 ° C at 9,000 rpm (Remi Centrifuge Pvt. Ltd., India).

The entrapment efficiency was counted by the equation (1).

$$\%EE = Mi - Mf / Mi \times 100 \quad \text{.....Equation (1)}$$

Where "Mi" is the initial drug mass used and "Mf" is the free drug mass detected in the sediment after centrifugation of the aqueous dispersion. Each value was calculated in triplicate. The final results are viewed as mean ± standard deviation.

Calorimetric Differential Scanning (DSC) data

Various formulating elements, placebo treatment SLNs, tranquilize stacked SLNs and physical blends have been exposed to DSC review (DSC-60, Shimadzu, Japan). In short, every drug sample (4–5 mg) was stored and sealed in the regular aluminum panes. The pans were then put under isothermal condition at 25 ± 1 ° C for about 10 minutes. DSC research was conducted in an inert atmosphere at 10 ° C / min, from 25 to 300 ° C. A vacant closed cassette was utilized for comparison.

Study of FTIR

According to (Bruecker, Germany) also we can use The Fourier Infrared Spectrometer (FTIR) to analyze infrared drug samples loaded with nanoparticles and physical mixtures by the FTIR spectrometer. Almost 1-2 mg only of each sample might be blended in with dry potassium bromide and checked in the transmission mode over a wavelength range from 400 to 4000 cm^{-1}.

Powder X-ray diffraction (PXRD)

All sorts of test of the drug model can be tested on SLN can be performed by an X-ray diffraction scale PXRD (Philips PW 1710, Tokyo, Japan), as CuKα radiation was utilized as source of x-ray. The units can also be set in glass test carriers for more precise analysis, and scanned from 10o to 40o at a scanning angle (2θ / min) of 2° / min with a voltage operating 40 kV and 30 mA and record the diffraction spectra.

Electrone scanning microscopy (SEM)

SEM can also be utilized to describe the treatment models microscopic structure loaded on S LN where SEM analysis can be performed via JSM-5610LV (JEOL Ltd, Tokyo, Japan). Specimen can be adhered to seed samples and then observed utilizing acceleration when zoomed. In the SEM study where electrons move in a free mood on the sample external surfaces. The image was captured in the idle state in the electron microscope.

Capacity steadiness of SLN

During prolonged storage, the physical properties of SLN's may be controlled by checking alters in the zeta potential, molecule size, medicate substance, appearance, and thickness as time work. Outer parameters, for example, temperature and light seem to be of essential significance for strength in the long term. Potential zeta must be in between -100 to + 100 mV to ensure a physically stable dispersion.

4°C - Most favorable storage temperature.

20°C – Durable packing did not cause aggregation or loss of drugs loaded with the SLN.

50°C - A rapid increase is observed in particle size.[67]

EVALUATING OF THE DRUG RELEASE

Drug release in vitro: Different methods used to test drug release in vitro which are:

Dialysis tubing

The release of drugs in vitro may be accomplished by means of dialysis tubing. The dispersion of solid lipid nanoparticles is put in pre-washed, hermetically sealable dialysis tubing. The dialysis sac is then dialyzed at room temperature opposing an acceptable dissolution medium, the specimen are extracted from the dissolving medium at acceptable intervals, centrifuged and analyzed for the medication content utilizing an appropriate analytical technique.

Reverse dialysis

Various little dialysis sacs comprising 1 ml of the medium of disintegration are put in SLN scattering in this technique. The SLN's are then transferred into the medium.

Franz Diffusion Cell

The scattering of the SLN is put in the Franz diffusion cell donor chamber which is equipped with a cellophane membrane. After that, the scattering is tested opposing an acceptable dissolution medium; the samples are extracted from the disintegration medium at appropriate interims and evaluated using acceptable methods for the product content like spectroscopy and HPLC methods.

SLN drug release principles can be listed as follows

a) A higher medication discharge may be given by the Higher surface territory due to little molecule measure in nanometer extent.
b) when the medication is homogenously scattered in the lipid framework the slow medication discharge can be accomplished. It relies on its type and SLN medication entanglement model.
c) Fast initial drug release in the first 5min in the drug - enriched shell model due to the particle outer layer because of larger surface area of drug deposition on the surface of particle.
d) As particle size increases the burst release is reduced what causes in the same time prolonging the release process there is a must should be followed and it is when the particles are sufficiently large, i.e., lipid macromolecules.
e) The surfactant sort and its concentration, that will interact with the external shell and affect greatly on its structure, should be noted as the external factor which is significant, since a poor surfactant concentration what brings in a small blast and delayed release of drugs.
f) The particle size affect on drug release rate significantly and it counts on several parameters like SLN formulation composition (like surfactant, lipid, drug) production method and conditions (like production time, equipment, sterilization and lyophilization [59,60].

APPLICATIONS OF SLN

SLNs for Chemotherapy

Neoplasm is the nickname of Cancer that characterized by the formation of abnormal tissues. Developed especially as a result of a change in the way that cells proliferate. nowadays, cancer is fighting drugs are poisonous to both tumor and typical cells, in this manner the chemotherapy efficiency is permanently bounded by the side effects resulted by the medication [68].

Lastly, a glimmer of hope has been provided by utilizing nanotechnology in cancer biology to develop novel cancer therapeutic strategies within scientific communities. Some nanoscale devices can be used as instruments to confront the cancer cells. This varies the drugs' selectivity to the cancer cells and it would certainly diminish the normal tissue poisonousness. Many reports are created to be devoted in order to describe lipid nanoparticles possibilities for parenteral delivery particularly for the cancer treatment. Over the twenty years, a great deal of extensive data has been obtained on essential biological procedures that are disrupted by cancer, for example, development factor restricting disruptions, gene transcription, signal transduction regulation, cell cycle checkpoints, apoptosis and angiogenesis which in their turn contributed to the quest for appropriate anti-cancer medications and created a record number of novel ingredients that are now utilized in cancer treatment studies. [69,70]. In another study, tamoxifen citrate loaded nanoparticles were injected in intravenously into rats and the parameters of pharmacokinetics were established. The t1/2 and mean residence time of TC-loaded SLNs in plasma was approximately 3.5-fold ($p < 0.001$) and 3-fold ($p < 0.001$) higher than free tamoxifen, suggesting the capacity of TC-loaded SLNs as a long blood circulation system. Accordingly the aforesaid strong lipid nanoparticles might be a useful method for delivering tamoxifen of tissues of cancer by improved porousness and maintenance impact (EPR) [71].

SLNs for Topical use

The methods of medication – molecule collaborations greatly affect drug conveyance by nanoparticulate bearer frameworks and the infiltration of medications through the skin. The exact charging process and release of the drug are still unclear. Hence the loading process, the agent interaction and the solid lipid nanoparticles (SLNs) lipid matrix besides, par electric spectroscopy and Electron spin resonance (ESR) (PS) studied the loaded agent absorption by skin lipids utilizing spin probes (TEMPO, TEMPOL, and CAT-1) as typical medications varying in lipophilicity. The

spin probes were either tightly connected to the lipid surface particles (TEMPO) or situated in the surfactant layers (CAT-1), respectively. In addition, two different sections divisions have been located on the SLN. Skin lipid blends were made to model the procedures at the SLN dispersal / skin stage boundary and ESR tomography comes after the transmission procedure of the spin labels. Transmission levels were respectively associated with the lipophilicity of the spin test, the lipid mixture, and the medical preparation applied, SLN scattering, and watery solution. SLN particularly hastened the circulation of lipophilic agents.

Corticosteroids are therapeutic agents generally used in treating diseases of skin like eczema or psoriasis. Topical SLN products show huge prospective for treating dermatological conditions by focusing on corticosteroids to dermal disease sites while decreasing systemic drug absorption. Topical use of the medicines at the pathological locales provides potential points of interest in distributing the medication straight to the place in act [72]. SLNs are used for topical application for various drugs like anticancer, vitamin-A, isotretinoin, flurbiprofen. Using glyceryl behenate, vitamin A-loaded nanoparticles can be prepared. This method is suitable and useful for penetration improvement with permanent release. The lipid nanoparticles filled with isotretinoin have been developed for topical conveyance of the medication. Production of the flurbiprofen-loaded SLN gel for topical application offer a possible benefit of drug delivery the drug directly to the place of work, which will deliver higher tissue focuses [73,74]. Doxorubicin (Dox) dermal delivery should be an perfect way to improve medication efficacy against skin cancer and reduce side effects [75].

Oral tests for medical products

Oral medication organization is a popular and supported path dependent on great patient obedience, non-obtrusiveness and remedial effectiveness, however low water-solvency of medications limits the stage for their retention. So we need a technique to boost product bioavailability. For this reason, the lipid-based conveyance frameworks have displayed several advances in recent decades. These frameworks incorporate a wide scope of details, for example, self-nanoemulsifying medication conveyance framework (SNEDDS), self-micro emulsifying drug conveyance framework (SMEDDS), nanoemulsions, SLNs and NLCs. As drugs are dissolved in the lipid in these systems, this allows the potential to improve the bioavailability of ineffectively dissolvable medications in water, particularly lipophilic medications. Indeed, these structures have the ability to rise substance release, residence time and lymphatic uptake. That is positive is that in most cases poisonousness has not been detected.

NLC can exploit all the advantages known from lipid nanoparticles for oral administration. Compared to the other systems, drug loading can be increased, drug inclusion is improved. NLC can easier be processed to forms notable to the patient in conventional dosing, for example. Tablet, Pellet or Capsule. Due to the high concentration of particles and cream-like consistency the NLC dispersions may be directly filled into capsules when producing the particles in an appropriate scattering medium, e. g. PEG 600, oil. The high particle concentration facilitates the use of these dispersions for granulation, or as a pellet wetting agent.

It also seems plausible that the dispersion of cream-like particles can be packed into tubes. Using a special dosing device, the patient can take the correct amount of medication on a spoon. This will be a easy and flexible program for individual dosage of, for example, SLN cyclosporine [76].

Oral SLN in Antitubercular Chemotherapy

Antitubercular medications like, isoniazide, rifampsin, SLN structures equipped with pyrazinamide have been capable to decrease dosing recurrence and increase patient obedience. SLNs filled with antituberculous drugs is prepared using solvent diffusion techniques [77].

SLNS as Cosmeceuticals

Cosmeceuticals are growing since these carriers' vital goal for application. Carrier systems such as SLNs and NLC have been designed to meet production criteria such as scale-up, certification and authentication, clear technology, low cost etc… [78]. The SLNs were used in sunscreen preparation and as an active carrier agent for molecular sunscreens and UV blockers. SLN and NLCs have proved to be controlled release innovative occlusive topicals. Better localization has been accomplished for vitamin A in upper layers of skin with glyceryl behenate SLNs compared to conventional formulations. In early 2005 the initial two beautifying production items comprising lipid nanoparticles appeared on the market [79].

SLNs as Gene Vector Carrier

SLN can be used in formulating gene vectors. several reports recently appeared about SLN bearing genetic/peptide constituents for example DNA, plasmid DNA and other nucleic acids The gene transfer was identified when a diametric HIV-1 HAT peptide was inserted into the SLN gene vector. The lipid nucleic acid nanoparticles were set up from a fluid nano process comprising water and a non-miscible natural dissolvable where lipid and DNA are melted separately by extracting the organic solvent, stable and homogeneous lipid nucleic acid nanoparticles (70-100 nm). It is known as genosphere. It is directly attacked by injecting in the particle an antibody-lipo polymer conjugated [80].

SLNs in Metastases of the breast and lymph nodes

Injections of mitoxantrone-charged SLN have been advanced to lessen toxicity and enhance the protection and bioavailability of doxorubicin (Dox) product efficacy through integration in SLNs. Throughout the technique, the Dox was mixed with anionic polymer centered on soybean - oil and dispersed along with a lipid throughout water to formulate stable lipid nanoparticles loaded with dox. The program has improved its effectiveness and decreased the number of cells of breast cancer [81,82].

SLNs as a Targeted Carrier for Solid Tumor Anticancer Drugs

SLNs have been accounted for as being valuable as medication bearers for treating neoplasms. Tumor goal was reached with drug-stacked SLNs, for example, methotrexate and camptothecin. Tamoxifen an anticancer medication is integrated in SLN to lengthen medication discharge after iv [83].

Stealth Nanoparticles

This provide a novel and special method of drug delivery that the immune system evades rapid clearance. Such nanoparticles could aim particular cells. For several animal models Stealth SLNs have been effectively tried with marker particles and medications. Antibody called stealth Lipobodies display a surprisingly increased distribution to inaccessible sites of the target tissue [84].

Diabetes

Diabetes mellitus is considered one of the world's most serious metabolic illnesses. Add to this, diabetes-induced hyperglycemia and it is a severe pathological disorder that causes neurological and CV damage. Researchers often focus their most on that care should be taken of SLNs as bearers to secure peptides and proteins known for their susceptibility to different natural factors, for example, pH, temperature and ionic strength. Zhang et al equipped SLNs coated with octaarginine stearic acid as insulin carriers. Octaarginine is a cell-penetrating peptide that may promote the taking of some drugs by cell. The scale and insulin encapsulation of octaargin-coated SLNs was 162 nm and 77% respectively. Octaarginine-coated and non-coated SLNs rise cell absorption of Caco-2 by 2.3 and 18.4 times, respectively. The octaarginine-containing SLNs displayed a meaningfully hypoglycemic (3-fold) impact in rats in comparison to non-coated SLNs. Insulin Oral delivery may significantly improve and increase the life quality of diabetes patients who take insulin routinely by subcutaneous route [85,86].

SLNs for Potential Agriculture Application

The crucial oil taken from Artemisia arborescent L when combined in the SLN had the ability to decrease rapid evaporation in comparison to emulsions and the systems were used as an appropriate transporter of environmentally safe pesticides in agriculture. [87,88].

CONCLUSION AND FUTURE PERSPECTIVE

The excellent physical properties of SLN and its promising integration of active compounds and their related benefits, have made the SLN an attractive system for carrying colloidal drugs. The current review concerned in raising awareness about the field of nanotechnology in the delivery of medication and the context of the emergence of several types of literature that focused on the construction and functioning of solid lipid nanoparticles, nanoparticle transporters, lipid drug comparisons, etc. SLNs have already proved their value as good formulations in cosmetics and their similar fields for improving medical therapeutics. To leverage the wide uses of nanoparticulate formulations based on lipids, It is imperative that pharmaceutical industries specialize in developing new drug delivery systems and discovering new formulation techniques to promote and expand the SLNs. SLNs provides an affordable and patient-friendly method for drug administration through different routes to optimize efficacy while preventing adverse effects on non-target tissues. For more than two decades of investigation, the applying of SLN now and then appear to be more advanced. In parenteral formulations, they will offer more possibilities for many drugs with Weak solubility in the atmosphere, short half-lives and poor chemical stability. Moreover, SLN is likely to find more applications as targeted drug delivery systems which will "direct" Drug molecules of special interest to organs and to reduce the systemic toxicity. Thus they can provide solutions for APIs that failed clinical testing because of inadequate localization of the tissue.

REFERENCES

1. Bouwstra J.A., Honeywell-Nguyen P.L, M. Ponec ., G.S. Gooris, Structure of the skin barrier and its modulation by vesicular formulations, Prog Lipid Res, 42 :2003, 1-36.
2. Muller R.H., Mader K. , Gohla S., Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art, Eur J Pharm Biopharm, 50 : 2000, 161-177.
3. Siekmann B., Westesen K., Investigations on solid lipid nanoparticles prepared by precipitation in o/w emulsions, Eur. J. Pharm. Biopharm, 42 (1996) 104-109.
4. Kleinberg M., What is the current and future status of conventional amphotericin B, Int J Antimicrob Agents, 27 Suppl 1 :2006, 12-16.
5. Yardley V., Croft S.L., A comparison of the activities of three amphotericin B lipid formulations against experimental visceral and cutaneous leishmaniasis, Int J Antimicrob Agents, 13 : 2000, 243-248.
6. Alvarez-Roman R., Naik A., Kalia Y.N., Guy R.H., Fessi H., Enhancement of topical delivery from biodegradable nanoparticles, Pharm Res, 21 : 2004, 1818-1825.
7. Bouwstra J.A., Honeywell-Nguyen P.L., Gooris G.S., Ponec M., Structure of the skin barrier and its modulation by vesicular formulations, Prog Lipid Res, 42 : 2003, 1-36.
8. Bunjes H., Koch M.H., Westesen K., Effect of particle size on colloidal solid triglycerides, Langmuir, 16 : 2000, 5234-5241.
9. Uddhav S Bagul, Vrushali V Pisal, Nachiket V Solanki and Antara Karnavat, Current Status of Solid Lipid Nanoparticles: A Review, Modern Applications of Bioequivalence & Bioavailability, 3(4): (2018), 1-10
10. Andega S., Kanikkannan N., Singh M., Comparison of the effect of fatty alcohols on the permeation of melatonin between porcine and human skin, J Control Release, 77 : 2001, 17-25.
11. Gupta M., Vyas S.P., Development, characterization and in vivo assessment of effective lipidic nanoparticles for dermal delivery of fluconazole

against cutaneous candidiasis, Chem Phys Lipids, 165 : 2012, 454-461.
12. Trotta M., Ugazio E., Peira E., Pulitano C., Influence of ion pairing on topical delivery of retinoic acid from microemulsions, J Control Release, 86 : 2003, 315-321.
13. Maia C.S., Mehnert W., Schafer-Korting M., Solid lipid nanoparticles as drug carriers for topical glucocorticoids, Int J Pharm, 196 : 2000, 165-167.
14. Chen H., Chang X., Du D., Liu W., Liu J., Weng T., Yang Y., Xu H., Yang X., Podophyllotoxin-loaded solid lipid nanoparticles for epidermal targeting, J Control Release, 110 : 2006, 296-306.
15. Cevc G., Lipid vesicles and other colloids as drug carriers on the skin, Adv Drug Deliv Rev, 56 : 2004, 675-711.
16. Lin C.H., Chen C.H., Lin Z.C., Fang J.Y., Recent advances in oral delivery of drugs and bioactive natural products using solid lipid nanoparticles as the carriers. J Food Drug Anal 25(2): 2017, 219-234.
17. Pavankumar A.R., Parthiban S., A modern review on solid lipid nanoparticles as novel controlled drug delivery system. Ijrpns 3(4): 2014, 313-325.
18. Xie S.Y., Wang S.L., Zhao B.K., Han C., Wang M., Effect of PLGA as a polymeric emulsifier on preparation of hydrophilic protein-loaded solid lipid nanoparticles. Colloids Surf B Biointerfaces 67(2): 2008 199-204.
19. Neda Naseri, Hadi Valizadeh, Parvin Zakeri-Milani, Solid Lipid Nanoparticles and Nanostructured Lipid Carriers: Structure, Preparation and Application, Advanced Pharmaceutical Bulletin, 2015, 5(3), 305-313
20. Verma Surender, Makkar Deepika, Solid lipid nanoparticles: a comprehensive review, Journal of Chemical and Pharmaceutical Research, 2016, 8(8):102-114
21. Jaiswal S., Gupta G.D ., Recent advances in solid lipid nanoparticles and challenges. Iajpr 3(12): 2013, 1601-1611.
22. Nasimudeen R., Tabrez J.S., Ashraf G.M.D., Shakil S., Damanhouri G.A., Nanotechnology-based approaches in anticancer research. Int J Nanomedicine 7: 2012, 4391-4408.
23. Mathur V., Satrawala Y., Rajput M.S., Kumar P., Shrivastava P., Solid lipid nanoparticles in cancer therapy. Int J Drug Deliv 2(3): 2010, 192- 199.
24. Bhattacharjee A., Solid lipid nanoparticles technology as a novel platform for delivery of drugs. Indo Am j pharm Res 3(5): 2013, 4079-4097.
25. Annette Z.M.H., Schwarz C., Wolfgang M., Solid lipid nanoparticles (SLN) for controlled drug delivery-drug release and release mechanism. Eur J Pharm Biopharm 45(2): 1998, 149-155.
26. Geszke-Moritz M., Mortiz M., Solid lipid nanoparticles as attractive drug vehicles: composition, properties and therapeutic strategies. Mater Sci Eng C Mater Biol Appl 68: 2016, 982-994.
27. Cavalli R., Marengo E., Rodriguez L., Gasco M.R., Effects of some experimental factors on the production process of solid lipid nanoparticles, Eur. J. Pharm. Biopharm. 43 : 1996, 110-115.
28. MuÈller B.W., Mikroemulsionen als neue Wirkstoff-TraÈgersysteme, in: R.H. MuÈller, G.E. Hildebrand (Eds.), Pharmazeutische Technologie: Moderne Arzneiformen, Wissenschaftliche Verlagsgesellschaft, Stuttgart, 1998, 161-168.
29. Jaiswal S., Gupta G.D., Recent advances in solid lipid nanoparticles and challenges. Iajpr 3(12): 2013, 1601-1611.
30. Hashem F.M., Mohamed N., Khairy A., in vitro cytotoxicity and bioavailability of solid lipid nanoparticles containing tamoxifen citrate. Pharm Dev Technol 19(7): 2014, 824-832.
31. Rahul N., ArunKumar K.S., Priya K.V., Recent advances in solid lipid nanoparticle based drug delivery systems, J Biomed Sci and Res 3(2): 2011, 368-384.
32. Tupal A., Sabzichi M., Ramezani F., Kouhsoltani M., Hamishehkar H., Dermal delivery of doxorubicin-loaded solid lipid nanoparticles for the treatment of skin cancer. J Microencapsul 33(4): 2016, 372-380.
33. MuÈller R.H., Lucks J.S., ArzneistofftraÈger aus festen Lipidteilchen, Feste LipidnanosphaÈren (SLN), European Patent No. 0605497 : 1996.
34. MuÈller R.H., Schwarz C., Mehnert W., Lucks J.S., Production of solid lipid nanoparticles (SLN) for controlled drug delivery, Proc. Int. Symp. Control. Release Bioact. Mater. 20 : 1993, 480-481.
35. Gasco M.R., Method for producing solid lipid microspheres having a narrow size distribution, US Patent 5 250 236 :1993.
36. Gasco M.R., Solid lipid nanospheres from warm micro-emulsions, Pharm. Technol. Eur. 9 : 1997, 52-58.
37. Boltri L., Canal T., Esposito P.A., Carli F., Lipid nanoparticles: evaluation of some critical formulation parameters, Proc. Int. Symp. Control. Release Bioact. Mater. 20 : 1993, 346-347.
38. Morel S., Terreno E., Ugazio E., Aime S., Gasco M.R., NMR relaxometric investigations of solid lipid nanoparticles (SLN) containing gadolinium (III) complexes, Eur. J. Pharm. Biopharm. 45 : 1998, 157-163.
39. Carli F., Physical Chemistry and Oral Absorption of the Nanoparticulate Systems, 5e Rencentre Pharmapeptides 1999.
40. Schwarz C., Mehnert W., Lucks J.S., MuÈller R.H., Solid lipid nanoparticles (SLN) for controlled drug delivery. I. Production, characterization and sterilisation, J. Control. Release 30 : 1994, 83-96.
41. Weyhers H., Feste Lipid-Nanopartikel (SLN) fuÈr die gewebsspezi- fische Arzneistoffapplikation, Ph.D. thesis, Free University of Berlin : 1995.
42. Rainer H. MuÈller, Karsten MaÈder, Sven Gohla, Solid lipid nanoparticles (SLN) for controlled drug delivery ± a review of the state of the art, European Journal of Pharmaceutics and Biopharmaceutics 50 (2000) 161-177

43. Speiser P., Lipidnanopellets als TraÈgersystem fuÈr Arzneimittel zur peroralen Anwendung, European Patent EP 0167825 : 1990.
44. Westesen K., Siekmann B., Investigation of the gel formation of phospholipid-stabilized solid lipid nanoparticles, Int. J. Pharm. 151 : 1997, 35-45.
45. Siekmann B., Westesen K., Investigations on solid lipid nanoparticles prepared by precipitation in o/w emulsions, Eur. J. Pharm.Biopharm. 43 : 1996, 104-109.
46. Ekambaram P., Sathali A., Priyanka K., Solid lipid nanoparticles: a review. Sci Rev Chem Commun, 2(1): 2012, 80-102.
47. Kamble M.S., Vaidya K.K., Bhosale A.V., Chaudhari P.D., Solid lipid nanoparticles and nanostructured lipid carriers–an overview. Int J Pharm chem Biol Sci , 2(4): 2012, 681-91.
48. Kumar A., Badde S., Kamble R., Pokharkar V.B., Development and characterization of liposomal drug delivery system for nimesulide. Int J Pharm Pharm Sci , 2(4): 2010, 87-9.
49. Mukherjee S., Ray S., Thakur R.S., Solid lipid nanoparticles: A modern formulation approach in drug delivery system. Indian J. Pharm Sci, 71(4): 2009, 349-58.
50. Pardeshi C., Rajput P., Belgamwar V., Tekade A., Patil G., Chaudhary K., Solid lipid based nanocarriers: An overview. Acta Pharm, 62(4): 2012, 433-72.
51. Muller R.H., Radtke M., Wissing S.A., Solid lipid nanoparticles (sln) and nanostructured lipid carriers (nlc) in cosmetic and dermatological preparations. Adv Drug Deliv Rev , 54 (1): 131-155.
52. Das S., Chaudhury A., Recent advances in lipid nanoparticle formulations with solid matrix for oral drug delivery. AAPS PharmSciTech, 12(1): 2011, 62-76.
53. Guimarães K.L., Ré M.I., Lipid nanoparticles as carriers for cosmetic ingredients: The first (SLN) and the second generation (NLC). In: Beck R, Guterres S, Pohlmann A, editors. Nanocosmetics and Nanomedicines: New approaches for skin care. Germany: Springer: 2011.
54. Cavalli R., Marengo E., Rodriguez L., Gasco M.R., Effects of some experimental factors on the production process of solid lipid nanoparticles, Eur. J. Pharm. Biopharm. 43 : 1996, 110-115.
55. MuÈller B.W., Mikroemulsionen als neue Wirkstoff-TraÈgersysteme, in: R.H. MuÈller, G.E. Hildebrand (Eds.), Pharmazeutische Technologie: Moderne Arzneiformen, Wissenschaftliche Verlagsgesellschaft, Stuttgart, 1998, 161-168.
56. Silva A.C., Kumar A., Wild W., Ferreira D., Santos D., Forbes B., Long-term stability, biocompatibility and oral delivery potential of risperidone-loaded solid lipid nanoparticles. Int J Pharm , 436(1-2): 2012, 798-805.
57. Padhye S.G., Nagarsenker M.S., Simvastatin solid lipid nanoparticles for oral delivery: Formulation development and in vivo evaluation. Indian J Pharm Sci,75(5): 2013, 591-8.
58. Mu H., Holm R., Mullertz A., Lipid-based formulations for oral administration of poorly water-soluble drugs. Int J Pharm , 453(1): 2013, 215-24.
59. Jawahar N., Meyyanathan S.N., Reddy G., Sood S., Solid lipid nanoparticles for oral delivery of poorly soluble drugs. J Pharm Sci Res, 4(7): 2012, 1848-55.
60. Uner M., Yener G., Importance of solid lipid nanoparticles (sln) in various administration routes and future perspectives. Int J Nanomedicine, 2(3): 2007, 289-300.
61. Yuan H., Huang L.F., Du Y.Z., Ying X.Y., You J., H.u F.Q., Solid lipid nanoparticles prepared by solvent diffusion method in a nanoreactor system. Colloids Surf B Biointerfaces, 61(2): 2008, 132-7.
62. Mukherjee S., Ray S., Thakur R.S., Solid lipid nanoparticles: A modern formulation approach in drug delivery system. Indian J Pharm Sci,71(4): 2009, 349-58.
63. Tamjidi F., Shahedi M., Varshosaz J., Nasirpour A., Nanostructured lipid carriers (NLC): A potential delivery system for bioactive food molecules. Innov Food Sci Emerg Tech, 19(0): 2013, 29-43.
64. Beloqui A., Solinis M.A., des R.A., Preat V., Rodriguez-Gascon A., Dextran-protamine coated nanostructured lipid carriers as mucus-penetrating nanoparticles for lipophilic drugs. Int J Pharm, 468(1-2): 2014, 105-11
65. Doktorovova S., Souto E.B., Silva A.M., Nanotoxicology applied to solid lipid nanoparticles and nanostructured lipid carriers - a systematic review of in vitro data. Eur J Pharm Biopharm , 87(1): 2014, 1-18.
66. Araujo J., Gonzalez-Mira E., Egea M.A., Garcia M.L., Souto E.B., Optimization and physicochemical characterization of a triamcinolone acetonide-loaded nlc for ocular antiangiogenic applications. Int J Pharm , 393(1-2): 2010, 167-75.
67. Wolfgang M., Karsten M.,Solid lipid nanoparticles production, characterization and applications. Adv Drug Deliv Rev 47(2-3): 2001,165- 196.
68. Cipolla D., Shekunov B., Blanchard J., Hickey A., Lipid-based carriers for pulmonary products: Preclinical development and case studies in humans. Adv Drug Deliv Rev, 75: 2014, 53-80.
69. Jaiswal P., Gidwani B., Vyas A., Nanostructured lipid carriers and their current application in targeted drug delivery. Artif Cells Nanomed Biotechnol :2014.
70. Kumar S., Dilbaghi N., Saharan R., Bhanjana G., Nanotechnology as Emerging Tool for Enhancing Solubility of Poorly Water-Soluble Drugs. Bio Nano Sci, (4): 2012, 227-50.
71. Jagdevappa P., Prashant G., Ravindra K., Sachin J., Satish M., Meghanath S., Applications of Solid Lipid Nanoparticle in Novel Drug Delivery System. Br Biomed Bull,1(2): 2013, 103-18.
72. D. Butani, C. Yewale, A. Misra. Amphotericin B topical microemulsion: Formulation, characterization and evaluation. Colloids Surf B Biointerfaces, 116 (2014) 351–35.

73. B.A. Grzybowski, W.T.S. Huck, The nanotechnology of life-inspired systems, Nat. Nanotechnol. 11 (2016) 585–592.
74. F. Araújo et al., Safety and toxicity concerns of orally delivered nanoparticles as rug carriers, Expert Opin. Drug Metab. Toxicol. 11 (2015) 381–393.
75. I.A. Lie et al., Treatment non-adherence as a trigger for status epilepticus: An observational, retrospective study based on therapeutic drug monitoring, Epilepsy Res. 113 (2015) 28–33.
76. A. Talevi, Computational approaches for innovative antiepileptic drug discovery., Expert Opin. Drug Discov. 11 (2016) 1001–16.
77. M. Mula, Third generation antiepileptic drug monotherapies in adults with epilepsy, Expert Rev. Neurother. 16 (2016) 1087–1092.
78. Z. Fang et al., Pluronic P85-coated poly(butylcyanoacrylate) nanoparticles overcome phenytoin resistance in P-glycoprotein overexpressing rats with lithium-pilocarpineinduced chronic temporal lobe epilepsy, Biomaterials. 97 (2016) 110–121.
79. D. Sakthivel, G. Arunachalam, Preparation and characterization of polymeric nanoparticles used in the treatment of epilepsy, 9 (2017) 298–301.
80. A. Lopalco et al., Oxcarbazepine-loaded polymeric nanoparticles: development and permeability studies across in vitro models of the blood-brain barrier and human placental trophoblast, Int. J. Nanomedicine. 10 (2015) 1985–96.
81. G. Vignaroli et al., Improvement of pyrazolo[3,4-d]pyrimidines pharmacokinetic properties: nanosystem approaches for drug delivery, Sci. Rep. 6 (2016) 21509.
82. G. Graverini et al., Solid lipid nanoparticles for delivery of andrographolide across the blood-brain barrier: in vitro and in vivo evaluation, Colloids Surfaces B Biointerfaces. 161 (2018) 302–313.
83. N. Gandomi et al., Solid lipid nanoparticles surface modified with anti-Contactin-2 or anti-Neurofascin for brain-targeted delivery of medicines, Pharm. Dev. Technol. 22 (2017) 426–435.
84. R. Dal Magro et al., ApoE-modified solid lipid nanoparticles: A feasible strategy to cross the blood-brain barrier, J. Control. Release. 249 (2017) 103–110.
85. A. Loureiro et al., Albumin-Based Nanodevices as Drug Carriers, Curr. Pharm. Des. 22 (2016) 1371–1390.
86. M. Bankstahl et al., Knockout of P-glycoprotein does not alter antiepileptic drug efficacy in the intrahippocampal kainate model of mesial temporal lobe epilepsy in mice, Neuropharmacology. 109 (2016) 183–95.
87. Muchow M., Maincent P., Muller R.H., Lipid nanoparticles with a solid matrix (sln, nlc, ldc) for oral drug delivery. Drug Dev Ind Pharm,34(12): 2008, 1394-405.
88. Sarathchandiran I., A Review on Nanotechnology in Solid Lipid Nanoparticles. Int J Pharm Deve Tech, 2(1): 2012, 45-61.